These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 30937539)

  • 1. How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-Domain.
    Anzengruber J; Feichtinger M; Bärnthaler P; Haider N; Ilas J; Pruckner N; Benamara K; Scheiflinger F; Reipert BM; Malisauskas M
    Pharm Res; 2019 Apr; 36(5):77. PubMed ID: 30937539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
    Gruppo RA; Brown D; Wilkes MM; Navickis RJ
    Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relevance of factor VIII (FVIII) pharmacokinetics to TDM and hemophilia a treatment: is B domain-deleted FVIII equivalent to full-length FVIII?
    Johnston A
    Ther Drug Monit; 2012 Feb; 34(1):110-7. PubMed ID: 22249347
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products.
    Jankowski W; Park Y; McGill J; Maraskovsky E; Hofmann M; Diego VP; Luu BW; Howard TE; Kellerman R; Key NS; Sauna ZE
    Blood Adv; 2019 May; 3(9):1429-1440. PubMed ID: 31053570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance.
    Grancha S; Ortiz AM; Marañón C; Hampel K; Moret A; Zimmermann B; Jorquera JI; Aznar JA
    Haemophilia; 2012 Nov; 18(6):982-9. PubMed ID: 22646163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, coagulation factor consumption and clinical efficacy in patients being switched from full-length FVIII treatment to B-domain-deleted r-FVIII and back to full-length FVIII.
    Rea C; Dunkerley A; Sørensen B; Rangarajan S
    Haemophilia; 2009 Nov; 15(6):1237-42. PubMed ID: 19664015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the B domain in proteolytic inactivation of activated coagulation factor VIII by activated protein C and activated factor X.
    Khrenov AV; Ananyeva NM; Saenko EL
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):379-88. PubMed ID: 16788314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of marketed factor VIII products: recombinant products are not alike vis-a-vis soluble protein aggregates and subvisible particles.
    Anzengruber J; Lubich C; Prenninger T; Gringeri A; Scheiflinger F; Reipert BM; Malisauskas M
    J Thromb Haemost; 2018 Jun; 16(6):1176-1181. PubMed ID: 29665242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defining 'full-length' recombinant factor VIII: a comparative structural analysis.
    Jankowski MA; Patel H; Rouse JC; Marzilli LA; Weston SB; Sharpe PJ
    Haemophilia; 2007 Jan; 13(1):30-7. PubMed ID: 17212722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative analysis of heterogeneity in commercially available recombinant factor VIII products.
    Baunsgaard D; Nielsen AD; Nielsen PF; Henriksen A; Kristensen AK; Bagger HW; Ezban M
    Haemophilia; 2018 Nov; 24(6):880-887. PubMed ID: 29726070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective analysis of differences in annual factor VIII utilization among haemophilia A patients.
    Epstein J; Xiong Y; Woo P; Li-McLeod J; Spotts G
    Haemophilia; 2012 Mar; 18(2):187-92. PubMed ID: 21883704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical characterisation of rVIII-SingleChain, a novel recombinant single-chain factor VIII.
    Schmidbauer S; Witzel R; Robbel L; Sebastian P; Grammel N; Metzner HJ; Schulte S
    Thromb Res; 2015 Aug; 136(2):388-95. PubMed ID: 26037285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Confocal microscopy analysis of native, full length and B-domain deleted coagulation factor VIII trafficking in mammalian cells.
    Becker S; Simpson JC; Pepperkok R; Heinz S; Herder C; Grez M; Seifried E; Tonn T
    Thromb Haemost; 2004 Jul; 92(1):23-35. PubMed ID: 15213841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein.
    Leksa NC; Chiu PL; Bou-Assaf GM; Quan C; Liu Z; Goodman AB; Chambers MG; Tsutakawa SE; Hammel M; Peters RT; Walz T; Kulman JD
    J Thromb Haemost; 2017 Jun; 15(6):1167-1179. PubMed ID: 28397397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Purification of recombinant human B-domain-deleted factor VIII using anti-factor VIII monoclonal antibody selected by the surface plasmon resonance biosensor.
    Oh HK; Lee JM; Byun TH; Park SY; Kim YH
    Biotechnol Prog; 2001; 17(6):1119-27. PubMed ID: 11735450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile.
    Pahl S; Pavlova A; Driesen J; Müller J; Pötzsch B; Oldenburg J
    Haemophilia; 2013 May; 19(3):392-8. PubMed ID: 23252674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of recombinant factor VIII B-domain induces phospholipid vesicle aggregation: implications for the immunogenicity of factor VIII.
    Grushin K; Miller J; Dalm D; Parker ET; Healey JF; Lollar P; Stoilova-McPhie S
    Haemophilia; 2014 Sep; 20(5):723-31. PubMed ID: 24750465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological activity of a new recombinant human coagulation factor VIII and its efficacy in a small animal model.
    Wu J; Zhang H; Lian T; Ding Y; Song C; Li D; Wu L; Lei T; Liang H
    Biochem Biophys Res Commun; 2023 Jan; 640():80-87. PubMed ID: 36502635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII.
    Qu J; Ma C; Xu XQ; Xiao M; Zhang J; Li D; Liu D; Konkle BA; Miao CH; Li L; Xiao W
    PLoS One; 2020; 15(5):e0233576. PubMed ID: 32442215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterogeneity in the tyrosine sulfation of Chinese hamster ovary cell produced recombinant FVIII.
    Mikkelsen J; Thomsen J; Ezban M
    Biochemistry; 1991 Feb; 30(6):1533-7. PubMed ID: 1899619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.